Target intelligence / Profile preview

Superoxide dismutase 1 aggregates (SOD1 aggregates) (SOD1 aggregates)

Target
SOD1 aggregates
Molecular classification
Enzyme, Protein aggregate
01

Overview

Superoxide dismutase 1 (SOD1) is a primary antioxidant enzyme that converts superoxide radicals into hydrogen peroxide and oxygen (UniProt P00441). In familial Amyotrophic Lateral Sclerosis (ALS), mutations in the SOD1 gene lead to the formation of misfolded protein species that assemble into toxic aggregates (PubMed: 29461114). These SOD1 aggregates are thought to exert a gain-of-toxic function, disrupting cellular processes such as mitochondrial activity, proteasomal degradation, and axonal transport within motor neurons (PubMed: 30271145). Therapeutic interventions like Tofersen, an antisense oligonucleotide, work by reducing the synthesis of SOD1 mRNA to decrease the overall protein load and subsequent aggregation (FDA, 2023). Other approaches include small molecules that stabilize the SOD1 dimer or antibodies designed to selectively clear misfolded SOD1 species (ClinicalTrials.gov: NCT05039099).

Other names
Misfolded SOD1SOD1 inclusionsMutant SOD1 aggregatesSuperoxide dismutase [Cu-Zn] aggregatesAmyotrophic lateral sclerosis 1 protein
02

Mechanism of action

Therapeutic strategies include the use of antisense oligonucleotides (ASOs) to degrade SOD1 mRNA and reduce protein expression, small molecule chaperones to stabilize the native SOD1 dimer, and monoclonal antibodies to target and clear extracellular misfolded SOD1 (PubMed: 33613465; FDA, 2023).

03

Biological functions

Superoxide metabolic processResponse to oxidative stressInduction of apoptosis (pathological)
04

Disease associations

Amyotrophic lateral sclerosisNeurodegenerative disease
05

Safety considerations

Risk of myelitis and chemical meningitis associated with intrathecal administration (FDA, 2023)Potential for off-target gene silencingInflammatory responses to immunotherapies
06

Interacting drugs

Tofersen

3 more in the full profile.

07

Biomarkers

Neurofilament light chain (NfL) in plasma and CSF (PubMed: 37133531)SOD1 protein concentration in cerebrospinal fluid

Beyond the preview

Go deeper on Superoxide dismutase 1 aggregates (SOD1 aggregates) (SOD1 aggregates).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Superoxide dismutase 1 aggregates (SOD1 aggregates) (SOD1 aggregates).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call